Figure 5.

(a) Diminished α_Vβ₃-integrin contrast enhancement in a T₁-weighted 3D gradient echo magnetic resonance (1.5 T) single slice image of a VX2 rabbit tumor following α_Vβ₃-targeted fumagillin nanoparticles versus (b) those given α_Vβ₃-targeted nanoparticles without drug. (Enhancing pixels are color coded in yellow.) (c) 3D angiogenesis maps in VX2 tumors following α_Vβ₃-targeted fumagillin nanoparticles versus (d) α_Vβ₃-nanoparticles without drug.³⁶